The evidence-based pharmacological treatment of paediatric ADHD

Brigette S. Vaughan, John S. March, Christopher J Kratochvil

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Attention deficit hyperactivity disorder (ADHD) is common in children, adolescents, and adults, with extensive research establishing it as a valid neurobiological disorder. Without intervention, ADHD can result in significant impairment throughout the lifespan for the individuals it afflicts. Fortunately, multiple evidence-based options are available for the treatment of ADHD, including several efficacious pharmacotherapies. The role of medication, including stimulants as well as non-stimulants, is well-documented by an extensive body of literature. Although there may be less enthusiasm for behavioural and other psychosocial interventions as stand-alone treatments for moderate to severe ADHD, they are recommended as first-line treatment for ADHD management in preschool-aged children, for those patients with mild symptoms, and as an adjunct to medication in patients with comorbid disorders or suboptimal responses to pharmacotherapy. When planning treatment for individuals with ADHD, the potential risks associated with the available interventions must be carefully balanced against the risks of not treating, or not treating adequately. The treatment plan must also include ongoing re-assessment of the effectiveness of and the need for continued therapy. Recent practice parameters provide further specific guidance for the evidence-based assessment and treatment of children and adolescents with ADHD.

Original languageEnglish (US)
Pages (from-to)27-39
Number of pages13
JournalInternational Journal of Neuropsychopharmacology
Volume15
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Attention Deficit Disorder with Hyperactivity
Pharmacology
Pediatrics
Therapeutics
Drug Therapy
Needs Assessment
Preschool Children
Research

Keywords

  • ADHD
  • attention
  • hyperactivity
  • pharmacotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

The evidence-based pharmacological treatment of paediatric ADHD. / Vaughan, Brigette S.; March, John S.; Kratochvil, Christopher J.

In: International Journal of Neuropsychopharmacology, Vol. 15, No. 1, 01.02.2012, p. 27-39.

Research output: Contribution to journalArticle

@article{7314f8359b4544d292d6edf26a8b0128,
title = "The evidence-based pharmacological treatment of paediatric ADHD",
abstract = "Attention deficit hyperactivity disorder (ADHD) is common in children, adolescents, and adults, with extensive research establishing it as a valid neurobiological disorder. Without intervention, ADHD can result in significant impairment throughout the lifespan for the individuals it afflicts. Fortunately, multiple evidence-based options are available for the treatment of ADHD, including several efficacious pharmacotherapies. The role of medication, including stimulants as well as non-stimulants, is well-documented by an extensive body of literature. Although there may be less enthusiasm for behavioural and other psychosocial interventions as stand-alone treatments for moderate to severe ADHD, they are recommended as first-line treatment for ADHD management in preschool-aged children, for those patients with mild symptoms, and as an adjunct to medication in patients with comorbid disorders or suboptimal responses to pharmacotherapy. When planning treatment for individuals with ADHD, the potential risks associated with the available interventions must be carefully balanced against the risks of not treating, or not treating adequately. The treatment plan must also include ongoing re-assessment of the effectiveness of and the need for continued therapy. Recent practice parameters provide further specific guidance for the evidence-based assessment and treatment of children and adolescents with ADHD.",
keywords = "ADHD, attention, hyperactivity, pharmacotherapy",
author = "Vaughan, {Brigette S.} and March, {John S.} and Kratochvil, {Christopher J}",
year = "2012",
month = "2",
day = "1",
doi = "10.1017/S1461145711000095",
language = "English (US)",
volume = "15",
pages = "27--39",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "1",

}

TY - JOUR

T1 - The evidence-based pharmacological treatment of paediatric ADHD

AU - Vaughan, Brigette S.

AU - March, John S.

AU - Kratochvil, Christopher J

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Attention deficit hyperactivity disorder (ADHD) is common in children, adolescents, and adults, with extensive research establishing it as a valid neurobiological disorder. Without intervention, ADHD can result in significant impairment throughout the lifespan for the individuals it afflicts. Fortunately, multiple evidence-based options are available for the treatment of ADHD, including several efficacious pharmacotherapies. The role of medication, including stimulants as well as non-stimulants, is well-documented by an extensive body of literature. Although there may be less enthusiasm for behavioural and other psychosocial interventions as stand-alone treatments for moderate to severe ADHD, they are recommended as first-line treatment for ADHD management in preschool-aged children, for those patients with mild symptoms, and as an adjunct to medication in patients with comorbid disorders or suboptimal responses to pharmacotherapy. When planning treatment for individuals with ADHD, the potential risks associated with the available interventions must be carefully balanced against the risks of not treating, or not treating adequately. The treatment plan must also include ongoing re-assessment of the effectiveness of and the need for continued therapy. Recent practice parameters provide further specific guidance for the evidence-based assessment and treatment of children and adolescents with ADHD.

AB - Attention deficit hyperactivity disorder (ADHD) is common in children, adolescents, and adults, with extensive research establishing it as a valid neurobiological disorder. Without intervention, ADHD can result in significant impairment throughout the lifespan for the individuals it afflicts. Fortunately, multiple evidence-based options are available for the treatment of ADHD, including several efficacious pharmacotherapies. The role of medication, including stimulants as well as non-stimulants, is well-documented by an extensive body of literature. Although there may be less enthusiasm for behavioural and other psychosocial interventions as stand-alone treatments for moderate to severe ADHD, they are recommended as first-line treatment for ADHD management in preschool-aged children, for those patients with mild symptoms, and as an adjunct to medication in patients with comorbid disorders or suboptimal responses to pharmacotherapy. When planning treatment for individuals with ADHD, the potential risks associated with the available interventions must be carefully balanced against the risks of not treating, or not treating adequately. The treatment plan must also include ongoing re-assessment of the effectiveness of and the need for continued therapy. Recent practice parameters provide further specific guidance for the evidence-based assessment and treatment of children and adolescents with ADHD.

KW - ADHD

KW - attention

KW - hyperactivity

KW - pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84856446255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856446255&partnerID=8YFLogxK

U2 - 10.1017/S1461145711000095

DO - 10.1017/S1461145711000095

M3 - Article

C2 - 21329553

AN - SCOPUS:84856446255

VL - 15

SP - 27

EP - 39

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 1

ER -